FDA requires longer term trials for HyQvia (Halozyme/Baxter) for Primary Immonodeficiency - 18-Apr-2012
The FDA wants additional safety data before it will complete its review of the biologics license application (BLA) for HyQvia, a combination of immune globulin infusion and recombinant human hyaluronidase (rHuPH20) from Halozyme and Baxter under investigation to treat primary immunodeficiency disorder.
Related News
Study shows safety and efficacy of Hizentra (CSL Behring) for treating Immunodeficiency
FDA issues Complete Response Letter for HyQ (Baxter) for treatment of Primary Immunodeficiencies
FDA requires longer term trials for HyQvia (Halozyme/Baxter) for Primary Immonodeficiency
HyQ (Baxter)brand name to be HyQvia for Immunodeficiency
Baxter files subcutaneous HyQ at EMA for Primary Immune Deficiency
Phase III study of Sufentanil NanoTab PCA System (AcelRx Pharmaceuticals) meets primary endpoint for Pain relief
FreeStyle InsuLinx Blood Glucose Monitoring System (Abbott) is recalled in the USA
Genous stent (Orbus Neich) has lower restenosis rate than bare metal stents in ACS treatment
Related Immunology Information
Immunology Clinical Guidelines
Multiple sclerosis: National clinical guideline for diagnosis and management in primary and secondary care
NICESwine flu clinical package
Department of HealthImmunology Clinical Trials
A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid Arthritis
Clinicaltrials.gov 11 April 2013A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
Clinicaltrials.gov 10 April 2013Immunology Medical Journal Abstracts
The combination of IKKβ inhibitor and everolimus modulates expression of IL-10 in HTLV-1-infected T cells
Immunology 27 December 2012The protective effect of a DNA vaccine encoding the Toxoplasma gondii cyclophilin gene in BALB/c mice
Parasite Immunology 27 December 2012
Advert for Healthcare Professionals only